doi.bio/syros_pharmaceuticals

Syros Pharmaceuticals

Summary

Syros Pharmaceuticals is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. The company is driven by the motivation to help patients with blood disorders that have largely eluded other targeted treatment approaches. Syros aims to redefine the power of small molecules to control gene expression and provide profound benefits for patients. Their focus is on cancer, including immuno-oncology, and genetic diseases.

History

Syros Pharmaceuticals was co-founded by Flagship Pioneering and is headquartered in Cambridge, Massachusetts, USA. The company was founded on November 9, 2011, by Richard A. Young, Nathanael S. Gray, and James E. Bradner.

Products and Pipeline

Syros has identified cancer patients with aberrant expression of genes that can be targeted with new therapies. Their gene control platform has allowed them to discover several targets for small molecule drugs, addressing certain cancers that have eluded other genomics-based approaches.

Their product candidates include:

• Tamibarotene: An oral selective RARα agonist for patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.
• SY-2101: A novel oral form of arsenic trioxide previously in clinical development for patients with acute promyelocytic leukemia.
• SY-5609: A highly selective and potent oral CDK7 inhibitor previously in clinical development for pancreatic cancer.
• SY-1425: Details unclear.
• SY-1365: A first-in-class selective CDK7 inhibitor.

Financial Information

Syros Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol 'SYRS'. As of April 2024, the company had 26.01 million shares outstanding and a revenue per employee of $75.17K.

Leadership and Employees

As of April 2024, Syros Pharmaceuticals had 97 employees, with a workforce comprising over 50% women. The company's leadership includes:

• Conley Chee: Participating in ongoing trials in MDS and AML.
• Mark Alles: Appointed to the Board of Directors in 2019.
• Dr. Nancy Simonian: CEO, recipient of the 2019 Pioneering Leader Award.

VC Investment

Syros Pharmaceuticals has received investment from Steven Cohen's Point72 Asset Management. The company has also partnered with Global Blood Therapeutics Inc. to develop and commercialize therapies for sickle cell disease and beta thalassemia.

Contact Information

Syros Pharmaceuticals, 35 CambridgePark Drive, Cambridge, MA 02140, USA.

References

Syros Pharmaceuticals. (n.d.). LinkedIn. Retrieved July 5, 2024, from https://www.linkedin.com/company/syros-pharmaceuticals

Syros Pharmaceuticals Inc. (SYRS). (n.d.). MarketWatch. Retrieved April 26, 2024, from https://www.marketwatch.com/investing/stock/syrs

Syros Pharmaceuticals, Inc. (SYRS). (n.d.). Yahoo Finance. Retrieved May 29, 2024, from https://finance.yahoo.com/quote/SYRS

Syros Pharmaceuticals | Flagship Pioneering. (n.d.). Flagship Pioneering. Retrieved April 3, 2024, from https://www.flagshippioneering.com/companies/syros-pharmaceuticals